Annual report pursuant to Section 13 and 15(d)

Goodwill and Other Intangible Assets

v3.20.4
Goodwill and Other Intangible Assets
12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets
8. Goodwill and Other Intangible Assets

 

Goodwill is attributable to the acquisition of the Biopharma business from CGI in July 2019. The carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million. The goodwill balance at December 31, 2019 was $8.4 million. The net carrying value of the identifiable intangible assets as of December 31, 2019 and December 31, 2018 is as follows:

 

          As Restated     As Restated  
          As of December 31, 2019     As of December 31, 2018  
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
                   
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       6,719       6,719  
BioPharma acquisition:                        
Trademarks     10       1,600       -  
Customer relationships     8       5,700       -  
                         
CLIA Lab     2.3     $ 609     $ 609  
                         
Total           $ 39,288     $ 31,988  
                         
Accumulated Amortization           $ (23,439 )   $ (19,450 )
                         
Net Carrying Value           $ 15,849     $ 12,538  

 

The following table displays a roll forward of the carrying amount of goodwill from January 1, 2018 to December 31, 2019:

 

    Carrying  
    Amount  
Balance as of January 1, 2018   $ -  
Balance as of December 31, 2018     -  
Goodwill acquired     8,273  
Adjustments     160  
Balance as of December 31, 2019   $ 8,433  

 

Amortization expense was approximately $4.0 million and $3.6 million for the years ended December 31, 2019 and 2018, respectively. Estimated amortization expense for the next five years is as follows:

 

As Restated  
2020     2021     2022     2023     2024  
                           
$ 4,871     $ 4,078     $ 2,156     $ 1,745     $ 873